LPA and cardiovascular disorder: Tsimikas et al. found that a novel therapeutic agent, i.e., APO(a)-LRx, provides potent reductions in levels of Lp(a) in patients with cardiovascular disease by reducing the production of apo(a) which offers greater specificity compared with PCSK9 inhibitor (17).